Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now

Abstract

Longterm treatment of parenterally administered interferon beta (IFNb) is one of the mainstays of multiple sclerosis (MS) therapy [1]. The first trials were conducted in the early 1980s when human fibroblast derived IFNb was administered intrathecally in an open-label fashion [2]. In ten patients treated monthly for 6 months a significant reduction of the… (More)
DOI: 10.1007/s00415-011-5941-0

Topics

2 Figures and Tables

Cite this paper

@article{Menge2011NeutralizingAI, title={Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now}, author={Til Menge and H. A. Hartung and Bernd C. Kieseier}, journal={Journal of Neurology}, year={2011}, volume={258}, pages={904-907} }